The use of long- and short-acting forms of gonadotrophin-releasing hormone analogues in women undergoing oocyte donation

By Neuspiller F   Levy M   Remohi J   Ruiz A   Simon C   Pellicer A  

Human Reproduction, Vol. 13, Iss. 5, 1998-05 ,pp. : 1148-1151

Oxford University Press

Access to resources Recommend Favorite

Influence of gonadotrophin-releasing hormone agonist total dose in the ovarian stimulation in the long down-regulation protocol for in-vitro fertilization

By Alvarez C.   Cremades N.   Blasco N.   Bernabeu R.  

Human Reproduction, Vol. 12, Iss. 11, 1997-11 ,pp. : 2366-2369

Oxford University Press

Access to resources Recommend Favorite

A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon®).

By ganirelix dose-finding study group The  

Human Reproduction, Vol. 13, Iss. 11, 1998-11 ,pp. : 3023-3031

Oxford University Press

Access to resources Recommend Favorite

Gonadotrophin-releasing hormone agonist dose-dependency of pituitary desensitization during controlled ovarian hyperstimulation in IVF

By Janssens RMJ   Vermeiden JPW   Lambalk CB   Schats R   Schoemaker J  

Human Reproduction, Vol. 13, Iss. 9, 1998-09 ,pp. : 2386-2391

Oxford University Press

Access to resources Recommend Favorite

Reducing the dose of gonadotrophin-releasing hormone agonist on starting ovarian stimulation: effect on ovarian response and in-vitro fertilization outcome

By Elgendy M   Afnan M  

Human Reproduction, Vol. 13, Iss. 9, 1998-09 ,pp. : 2382-2385

Oxford University Press

Access to resources Recommend Favorite